# arthropod borne diseases

Arthropod Borne Diseases Table



| Disease name | Causative organisms | Agent/vector | Agent factors | Source of infection | Infectivity | Secondary attack rate | Vector control measures | Age of host | Type of immunity | Special Effects during pregnancy if any | Environmental factors | Transmission | Incubation period | Clinical features | Complications | Diagnosis(all methods) | Prevention |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Malaria | Plasmodium species ( $P. vivax$ , $P. falciparum$ , $P. malariae$ , $P. ovale$ , $P. knowlesi$ ) | Female Anopheles mosquito ( $An. culicifacies$ , $An. stephensi$ , $An. fluviatilis$ ) | Complex life cycle: Schizogony (man), Sporogony (mosquito). $P. falciparum$ is most virulent; $P. vivax/Po$ have liver hypnozoites. | Human cases and carriers harboring mature, viable gametocytes in peripheral blood. | Mosquito infective 7–20 days after feeding. Human infective as long as viable gametocytes exist in blood. | Not in source | Indoor Residual Spraying (IRS) with DDT/Malathion; ITNs/LLINs; Larvivorous fish ( $Gambusia$ ); Source reduction (drainage). | All ages; infants/children more susceptible. Newborns have temporary resistance ( $HbF$ ). | Acquired immunity (premunition) via repeated exposure; species/strain specific; maternal $IgG$ protects for 3–5 months. | Increased risk of maternal anemia, placental infection, abortion, LBW delivery, and intrauterine death. $PQ$ contraindicated. | Stagnant clean water; Temp 20–30°C; Humidity $>60\%$ ; rainfall and irrigation facilitate breeding. | Bite of infected female Anopheles; blood transfusion; contaminated needles; congenital. | $P.f$ : 9–14 days; $P.v$ : 8–17 days; $P.m$ : 18–40 days; $P.o$ : 16–18 days. | Paroxysms (cold, hot, sweating stages); fever with rigors; splenomegaly; anemia; headache; nausea. | Cerebral malaria; Blackwater fever (hemoglobinuria); Renal failure; Pulmonary edema (ARDS); Algid malaria. | Microscopy (thick/thin smears); RDTs (HRP-2, pLDH); Serology (IFA); PCR. | Chemoprophylaxis (Doxycycline, Mefloquine); Vector control; RTS,S/AS01 ( $Mosquirix$ ) vaccine. |
| Dengue | Dengue virus (Serotypes DENV-1, 2, 3, 4) | Aedes aegypti and Aedes albopictus | Flavivirus; infection with one confers lifelong immunity to it but cross-protection is temporary. | Infected humans (viraemic stage) and mosquitoes (transovarial). | Human blood is infective 18h before onset to 3–5 days after. Mosquito infective after 8–10 days. | Not in source | Elimination of artificial water containers; Larvicides ( $Temephos$ ); Fogging ( $Malathion$ ); Dry day observance. | All ages; DHF predominantly in children $<15$ years; infants/elderly at high risk for severe disease. | Lifelong homologous immunity; heterologous infection increases risk of severe disease. | Increased risk of severe disease (DHF/DSS); maternal-fetal transmission possible. | Rapid urbanization; poor water storage; rainy season; Temp 16–30°C; Humidity 60–80%. | Bite of infected day-biting Aedes; rarely blood transfusion or vertical transmission. | 3–14 days (commonly 5–7 days). Extrinsic: 8–10 days. | Sudden high fever; bimodal (saddleback); retro-orbital pain; break-bone pain; maculopapular rash; petechiae. | Dengue Haemorrhagic Fever (DHF); Dengue Shock Syndrome (DSS); Plasma leakage; Thrombocytopenia. | NS1 Ag ELISA (early); IgM/IgG ELISA (after 5 days); RT-PCR; Tourniquet test; Hematocrit/Platelet count. | Vector control; Personal protection; CYD-TDV ( $Dengvaxia$ ) vaccine in specific regions. |
| Lymphatic filariasis | Wuchereria bancrofti, Brugia malayi, Brugia timori | Culex quinquefasciatus, Mansonia, Anopheles, Aedes | Adult worms live 5–15 years; microfilariae display nocturnal periodicity (10 PM – 2 AM). | Human microfilaria carriers. | Mosquito infective after 10–14 days. Man remains infective as long as microfilariae are in blood. | Not in source | Larvicides ( $Temephos$ ); Deweeding ( $Pistia$ plants for Mansonia); Environmental sanitation/drainage. | All ages; prevalence increases with age, peaking in early adult life ( $20-30$ years). | Not absolute; resistance develops only after many years of exposure. | Triple drug (DEC+IVM+ALB) and MDA excluded during pregnancy. | Unplanned urbanization; polluted water (Culex); aquatic plants (Mansonia); Humidity 70–80%. | Bite of infected mosquito; L3 larvae enter through skin portal of entry. | Clinical: 8–16 months. Pre-patent (Mf detection): 4 weeks to months. | Lymphadenitis; lymphangitis; asymptomatic microfilaraemia; fever (ADLA); hydrocele; elephantiasis. | Chronic obstructive lesions; permanent structural changes; Chyluria; Tropical Pulmonary Eosinophilia. | Microscopy (Night blood smears); Membrane filter concentration; DEC provocation test; Antigen detection (ICT). | Mass Drug Administration (MDA) with DEC, Albendazole, Ivermectin; Morbidity management. |
| Japanese encephalitis | Japanese Encephalitis Virus (JEV) | Culex mosquitoes (notably $C. tritaeniorhynchus$ , $C. vishnui$ ) | Flavivirus; zoonotic cycle involves pigs and ardeid birds. | Pigs (amplifying hosts) and Ardeid birds (herons/egrets). Man is a dead-end host. | Viraemia in man is low/short; mosquito remains infective for life. | 0 (No person-to-person transmission). | Insecticidal spraying of cattle sheds/pigsties; ULV fogging ( $Malathion$ ); rice field management. | Primarily children ( $<15$ years) in endemic areas; all ages in episodic areas. | Naturally acquired via subclinical infection; active immunity via vaccination. | Congenital infection possible. | Rice fields; irrigation systems; proximity to pig rearing; monsoon season; Temp 18–32°C. | Pig/Bird $\rightarrow$ Mosquito $\rightarrow$ Man; Accidental dead-end in humans. | 5–15 days. | Prodromal: Fever, headache, GI upset. Encephalitic: Altered sensorium, convulsions, nuchal rigidity. | Permanent neurological/psychiatric sequelae; motor abnormalities; Case Fatality Rate 20–40%. | IgM-capture ELISA (Serum/CSF); RT-PCR; Paired sera (IgG rise); virus isolation from brain. | Vaccination (SA 14-14-2, JENVAC); pig control; personal protection. |
| Chikungunya | Chikungunya virus | Aedes aegypti and Aedes albopictus | Alphavirus; single-strand RNA; virus multiplies in mosquito salivary glands. | Infected human cases; possibly wild primates. | High during epidemic outbreaks and viraemic stage. Extrinsic incubation $\approx 10$ days. | Not in source | Source reduction; ULV fogging; environmental sanitation; personal protection. | All ages. | Long-lasting immunity following infection. | Mother-to-child transmission at delivery; $IXCHIQ$ vaccine contraindicated. | Stagnant water in artificial containers; urbanization; rainy season peaks. | Bite of infected Aedes mosquito. | 3–12 days (commonly 3–7 days). | Sudden onset high fever; crippling joint pain (arthralgia); rash; headache; myalgia. | Chronic joint pain/arthritis persisting months or years; neurological manifestations. | Serology (IgM ELISA); RT-PCR; Virus isolation (Vero cells). | Vector control; Source reduction; $IXCHIQ$ vaccine (approved for $>18$ years). |
| Zika virus disease | Zika virus | Aedes aegypti and Aedes albopictus | Flavivirus; related to Dengue and Spondweni viruses. | Infected humans; reservoir in wild unknown. | Human viraemia lasts approx. 1 week. 1 in 5 infected become ill. | Not in source | Aedes control (source reduction); use of screens/nets; insect repellents ( $DEET$ ). | All ages. | Not in source | Associated with Microcephaly and other congenital malformations (Congenital Zika Syndrome). | Tropical and subtropical environments; Aedes breeding sites in domestic areas. | Mosquito bite; sexual transmission; blood transfusion; transplacental (mother-to-fetus). | 3–14 days. | Fever; maculopapular rash; conjunctivitis; muscle/joint pain; headache; malaise. | Guillain-Barré Syndrome; Microcephaly in newborns; rarely death. | RT-PCR (blood/urine/saliva); Serology (IgM ELISA - limited by cross-reactivity). | Mosquito avoidance; Barrier contraception (safe sex); Pregnancy planning in endemic areas. |
| Kyanasaur forest disease | KFD virus (KFDV) | Hard ticks (notably $Haemaphysalis spinigera$ ) | Flavivirus; SSR\_RNA virus; neurotropic and viscerotropic. | Wild rodents (rats, squirrels), monkeys (amplifying hosts), and ticks (reservoirs). | Death of monkeys is an indicator of outbreak; ticks remain infected for life. | 0 (No man-to-man transmission). | Spraying forest floors with acaricides ( $Carbaryl$ , $Fenthion$ ); cattle movement restriction. | Primarily adults (20–40 years) visiting forest areas (farmers, woodcutters). | Naturally acquired antibodies in endemic areas; vaccine-induced immunity. | Not in source | Deciduous forests; dry months (Jan–June); human activity in forest. | Bite of infected nymphal tick; handling dead infected monkeys. | 3–8 days. | Sudden high fever; headache; severe myalgia; prostration; haemorrhagic manifestations (nose/gums). | Second phase: Meningoencephalitis (tremors, mental confusion); Case fatality 4–16%. | RT-PCR; Virus isolation from blood; Serology (IgM ELISA, HI, Neutralizing antibodies). | Vaccination (Killed KFD vaccine); personal prophylaxis (protective clothing, DMP/DEET). |